Literature DB >> 9825485

The biology and clinical relevance of somatostatin receptor scintigraphy in adrenal tumor management.

J W Kennedy1, R G Dluhy.   

Abstract

Somatostatin receptors are present in the normal adrenal cortex and medulla. These receptors are also expressed by tumors that cause Cushing's syndrome and by pheochromocytomas. Somatostatin analogues such as octreotide have been developed to target somatostatin receptors for diagnostic and therapeutic purposes. This article reviews the current knowledge of the biology of somatostatin receptors in the normal adrenal gland and in adrenal tumors and defines the current role of the somatostatin receptor in the diagnosis, staging and management of Cushing's syndrome and pheochromocytomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9825485      PMCID: PMC2589262     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  30 in total

Review 1.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors.

Authors:  S W Lamberts; E P Krenning; J C Reubi
Journal:  Endocr Rev       Date:  1991-11       Impact factor: 19.871

2.  Somatostatin analog (SMS 201-995) inhibits the basal and angiotensin II-stimulated 3H-thymidine uptake by rat adrenal glands.

Authors:  M Pawlikowski; A Lewiński; E Sewerynek; M Szkudliński; J Kunert-Radek; E Wajs
Journal:  Biochem Biophys Res Commun       Date:  1990-02-14       Impact factor: 3.575

3.  Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome.

Authors:  M R Flack; E H Oldfield; G B Cutler; M H Zweig; J D Malley; G P Chrousos; D L Loriaux; L K Nieman
Journal:  Ann Intern Med       Date:  1992-02-01       Impact factor: 25.391

Review 4.  Somatostatin (second of two parts).

Authors:  S Reichlin
Journal:  N Engl J Med       Date:  1983-12-22       Impact factor: 91.245

Review 5.  Somatostatin.

Authors:  S Reichlin
Journal:  N Engl J Med       Date:  1983-12-15       Impact factor: 91.245

Review 6.  Octreotide.

Authors:  S W Lamberts; A J van der Lely; W W de Herder; L J Hofland
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

7.  Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (sandostatin).

Authors:  C Invitti; M de Martin; A Brunani; M Piolini; F Cavagnini
Journal:  Clin Endocrinol (Oxf)       Date:  1990-03       Impact factor: 3.478

8.  Somatostatin modulates effects of angiotensin II in adrenal glomerulosa zone.

Authors:  G Aguilera; J P Harwood; K J Catt
Journal:  Nature       Date:  1981-07-16       Impact factor: 49.962

9.  Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome.

Authors:  E H Oldfield; J L Doppman; L K Nieman; G P Chrousos; D L Miller; D A Katz; G B Cutler; D L Loriaux
Journal:  N Engl J Med       Date:  1991-09-26       Impact factor: 91.245

10.  Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.

Authors:  B Ambrosi; D Bochicchio; C Fadin; P Colombo; G Faglia
Journal:  J Endocrinol Invest       Date:  1990-03       Impact factor: 4.256

View more
  1 in total

1.  Does somatostatin have a role in the regulation of cortisol secretion in primary pigmented nodular adrenocortical disease (ppnad)? a clinical and in vitro investigation.

Authors:  Zakariae Bram; Paraskevi Xekouki; Estelle Louiset; Meg F Keil; Dimitrios Avgeropoulos; Christoforos Giatzakis; Maria Nesterova; Ninet Sinaii; Leo J Hofland; Rabia Cherqaoui; Hervé Lefebvre; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2014-02-10       Impact factor: 5.958

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.